This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Morbidity and Mortality Follow Up for the Scleroderma Lung Study

This study has been completed.
Information provided by (Responsible Party):
Duke University Identifier:
First received: January 4, 2013
Last updated: January 22, 2014
Last verified: January 2014
The primary intent of this study is to add to the body of knowledge on scleroderma patients with interstitial lung disease. While lung disease is recognized as the leading cause of death amongst patients with scleroderma, there is not a large body of literature describing the long-term morbidity and mortality rate of these scleroderma patients. For this reason, the investigators are following participants of the Scleroderma Lung Study (NCT00004563) after their participation in that study was concluded. In addition, the investigators will assess if the subjects who received one year of oral cyclophosphamide in the Scleroderma Lung Study experienced progression of their scleroderma-related lung disease following the end of the study.

Condition Intervention
Scleroderma Other: Followup survey

Study Type: Observational
Study Design: Observational Model: Cohort
Official Title: Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study 1

Resource links provided by NLM:

Further study details as provided by Duke University:

Primary Outcome Measures:
  • Time to death or first organ failure [ Time Frame: 9-12 years ]

Enrollment: 158
Study Start Date: July 2012
Study Completion Date: August 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Patients who received cyclophosphamide
Patients who received cyclophosphamide on the Scleroderma Lung Study
Other: Followup survey
Patients who received placebo
Patients who received placebo on the Scleroderma Lung Study
Other: Followup survey

Detailed Description:

Retrospective and prospective data will be collected about patients who participated in the Scleroderma Lung Study (SLS). An attempt will be made to include all of the participants of the Scleroderma Lung Study, who were reported as alive at the end of that study.

A total of 158 subjects (79 per treatment arm) were randomized on the original Scleroderma Lung Study. Of those, 109 subjects completed the study. A single telephone interview with the participants to assess the occurrence of severe events and a review of the participant's medical records may be conducted. The outcome information will be combined with information collected about all participants in the SLS study. The data being collected includes information on mortality, development of cancers, development of organ failure, and performance status.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients who participated in the Scleroderma Lung Study

Inclusion Criteria:

  • Participation in the Scleroderma Lung Study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01762449

Sponsors and Collaborators
Duke University
Study Chair: Keith Sullivan, MD Duke University
Study Chair: Daniel Furst, MD University of California, Los Angeles
Principal Investigator: Donald Tashkin, MD University of California, Los Angeles
  More Information

Responsible Party: Duke University Identifier: NCT01762449     History of Changes
Other Study ID Numbers: Pro00026357
Study First Received: January 4, 2013
Last Updated: January 22, 2014

Keywords provided by Duke University:
interstitial lung disease

Additional relevant MeSH terms:
Scleroderma, Systemic
Scleroderma, Diffuse
Scleroderma, Localized
Connective Tissue Diseases
Skin Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists processed this record on September 19, 2017